Stephens Investment Management Group LLC Decreases Stock Holdings in Henry Schein, Inc. $HSIC

Stephens Investment Management Group LLC lowered its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 6.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,619 shares of the company’s stock after selling 9,131 shares during the quarter. Stephens Investment Management Group LLC owned 0.11% of Henry Schein worth $9,001,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. CYBER HORNET ETFs LLC purchased a new position in Henry Schein in the second quarter worth about $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein in the 2nd quarter worth approximately $27,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Henry Schein during the 2nd quarter valued at approximately $43,000. Steph & Co. purchased a new stake in Henry Schein during the 2nd quarter valued at $44,000. Finally, CX Institutional lifted its position in Henry Schein by 107.3% in the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after buying an additional 337 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HSIC. Barclays initiated coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective on the stock. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Evercore ISI raised their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. increased their price target on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $76.33.

Henry Schein Price Performance

Shares of HSIC stock opened at $79.98 on Friday. The company has a market capitalization of $9.42 billion, a P/E ratio of 25.31, a P/E/G ratio of 2.38 and a beta of 0.88. The company’s 50-day simple moving average is $75.28 and its two-hundred day simple moving average is $70.53. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The firm had revenue of $3.34 billion during the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, equities analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.